Literature DB >> 19255328

Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes.

Roger M Lyons1, Thomas M Cosgriff, Sanjiv S Modi, Robert H Gersh, John D Hainsworth, Allen L Cohn, Heidi J McIntyre, Indra J Fernando, Jay T Backstrom, C L Beach.   

Abstract

PURPOSE: Azacitidine (AZA) is effective treatment for myelodysplastic syndromes (MDS) at a dosing schedule of 75 mg/m(2)/d subcutaneously for 7 days every 4 weeks. The initial phase of this ongoing multicenter, community-based, open-label study evaluated three alternative AZA dosing schedules without weekend dosing. PATIENTS AND METHODS: MDS patients were randomly assigned to one of three regimens every 4 weeks for six cycles: AZA 5-2-2 (75 mg/m(2)/d subcutaneously for 5 days, followed by 2 days no treatment, then 75 mg/m(2)/d for 2 days); AZA 5-2-5 (50 mg/m(2)/d subcutaneously for 5 days, followed by 2 days no treatment, then 50 mg/m(2)/d for 5 days); or AZA 5 (75 mg/m(2)/d subcutaneously for 5 days).
RESULTS: Of patients randomly assigned to AZA 5-2-2 (n = 50), AZA 5-2-5 (n = 51), or AZA 5 (n = 50), most were French-American-British (FAB) lower risk (refractory anemia [RA]/RA with ringed sideroblasts/chronic myelomonocytic leukemia with < 5% bone marrow blasts, 63%) or RA with excess blasts (30%), and 79 (52%) completed > or = six treatment cycles. Hematologic improvement (HI) was achieved by 44% (22 of 50), 45% (23 of 51), and 56% (28 of 50) of AZA 5-2-2, AZA 5-2-5, and AZA 5 arms, respectively. Proportions of RBC transfusion-dependent patients who achieved transfusion independence were 50% (12 of 24), 55% (12 of 22), and 64% (16 of 25), and of FAB lower-risk transfusion-dependent patients were 53% (nine of 17), 50% (six of 12), and 61% (11 of 18), respectively. In the AZA 5-2-2, AZA 5-2-5, and AZA 5 groups, 84%, 77%, and 58%, respectively, experienced > or = 1 grade 3 to 4 adverse events.
CONCLUSION: All three alternative dosing regimens produced HI, RBC transfusion independence, and safety responses consistent with the currently approved AZA regimen. These results support AZA benefits in transfusion-dependent lower-risk MDS patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19255328     DOI: 10.1200/JCO.2008.17.1058

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  82 in total

1.  Effects of azacitidine compared with conventional care regimens in elderly (≥ 75 years) patients with higher-risk myelodysplastic syndromes.

Authors:  John F Seymour; Pierre Fenaux; Lewis R Silverman; Ghulam J Mufti; Eva Hellström-Lindberg; Valeria Santini; Alan F List; Steven D Gore; Jay Backstrom; David McKenzie; C L Beach
Journal:  Crit Rev Oncol Hematol       Date:  2010-05-06       Impact factor: 6.312

Review 2.  Transforming growth factor (TGF)-β pathway as a therapeutic target in lower risk myelodysplastic syndromes.

Authors:  Jan Philipp Bewersdorf; Amer M Zeidan
Journal:  Leukemia       Date:  2019-04-08       Impact factor: 11.528

Review 3.  Safety and efficacy of azacitidine in elderly patients with intermediate to high-risk myelodysplastic syndromes.

Authors:  Shyamala C Navada; Lewis R Silverman
Journal:  Ther Adv Hematol       Date:  2016-10-20

4.  Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes.

Authors:  Mikkael A Sekeres; Alan F List; David Cuthbertson; Ronald Paquette; Rebecca Ganetzky; Rebecca Ganetsky; Deborah Latham; Katarina Paulic; Manuel Afable; Hussain I Saba; Thomas P Loughran; Jaroslaw P Maciejewski
Journal:  J Clin Oncol       Date:  2010-03-30       Impact factor: 44.544

5.  Hematology: Azacitidine improves survival in myelodysplastic syndromes.

Authors:  Michal G Rose
Journal:  Nat Rev Clin Oncol       Date:  2009-09       Impact factor: 66.675

Review 6.  Hypomethylating agents and other novel strategies in myelodysplastic syndromes.

Authors:  Guillermo Garcia-Manero; Pierre Fenaux
Journal:  J Clin Oncol       Date:  2011-01-10       Impact factor: 44.544

7.  Obstacles to adherence to azacitidine administration schedule in outpatient myelodysplastic syndrome and related disorders.

Authors:  Andrea Tendas; Maria Felicita Lissia; Daniela Piccioni; Liliana Tirimbelli; Laura Scaramucci; Marco Giovannini; Teresa Dentamaro; Alessio Perrotti; Paolo de Fabritiis; Pasquale Niscola
Journal:  Support Care Cancer       Date:  2014-11-05       Impact factor: 3.603

8.  A phase II study of the efficacy and safety of an intensified schedule of azacytidine in intermediate-2 and high-risk patients with myelodysplastic syndromes: a study by the Groupe Francophone des Myelodysplasies (GFM).

Authors:  Lionel Ades; Agnès Guerci-Bresler; Pascale Cony-Makhoul; Laurence Legros; Marie Sebert; Thorsten Braun; Jacques Delaunay; Kristell Desseaux; Sylvie Chevret; Pierre Fenaux
Journal:  Haematologica       Date:  2018-10-31       Impact factor: 9.941

9.  Optimizing outcomes with azacitidine: recommendations from Canadian centres of excellence.

Authors:  R A Wells; B Leber; N Y Zhu; J M Storring
Journal:  Curr Oncol       Date:  2014-02       Impact factor: 3.677

10.  Epigenetic approaches in the treatment of myelodysplastic syndromes: clinical utility of azacitidine.

Authors:  Steven E McCormack; Erica D Warlick
Journal:  Onco Targets Ther       Date:  2010-09-07       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.